CN115362254A - 抗原特异性结合多肽基因展示载体的构建方法与应用 - Google Patents
抗原特异性结合多肽基因展示载体的构建方法与应用 Download PDFInfo
- Publication number
- CN115362254A CN115362254A CN202180024143.4A CN202180024143A CN115362254A CN 115362254 A CN115362254 A CN 115362254A CN 202180024143 A CN202180024143 A CN 202180024143A CN 115362254 A CN115362254 A CN 115362254A
- Authority
- CN
- China
- Prior art keywords
- vector
- display
- polynucleotide
- antigen
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 title claims abstract description 544
- 239000000427 antigen Substances 0.000 title claims abstract description 266
- 108091007433 antigens Proteins 0.000 title claims abstract description 258
- 102000036639 antigens Human genes 0.000 title claims abstract description 258
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 119
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 119
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 119
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 55
- 238000010276 construction Methods 0.000 title description 20
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 188
- 239000012634 fragment Substances 0.000 claims abstract description 157
- 238000000034 method Methods 0.000 claims abstract description 142
- 230000001580 bacterial effect Effects 0.000 claims abstract description 121
- 230000009870 specific binding Effects 0.000 claims abstract description 86
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 44
- 230000027455 binding Effects 0.000 claims abstract description 40
- 102000004190 Enzymes Human genes 0.000 claims abstract description 6
- 108090000790 Enzymes Proteins 0.000 claims abstract description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 350
- 108091033319 polynucleotide Proteins 0.000 claims description 350
- 239000002157 polynucleotide Substances 0.000 claims description 350
- 241000894006 Bacteria Species 0.000 claims description 134
- 238000003776 cleavage reaction Methods 0.000 claims description 84
- 230000007017 scission Effects 0.000 claims description 84
- 238000003860 storage Methods 0.000 claims description 83
- 239000013612 plasmid Substances 0.000 claims description 63
- 210000004027 cell Anatomy 0.000 claims description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 43
- 238000012216 screening Methods 0.000 claims description 23
- 230000002255 enzymatic effect Effects 0.000 claims description 19
- 239000013604 expression vector Substances 0.000 claims description 19
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 18
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 18
- 102100039614 Nuclear receptor ROR-alpha Human genes 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 claims description 13
- 102000012410 DNA Ligases Human genes 0.000 claims description 7
- 108010061982 DNA Ligases Proteins 0.000 claims description 7
- 102000003960 Ligases Human genes 0.000 claims description 7
- 108090000364 Ligases Proteins 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 3
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 3
- 101710137302 Surface antigen S Proteins 0.000 claims description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 238000005520 cutting process Methods 0.000 abstract description 2
- 108010042407 Endonucleases Proteins 0.000 description 44
- 102100031780 Endonuclease Human genes 0.000 description 42
- 239000002773 nucleotide Substances 0.000 description 38
- 125000003729 nucleotide group Chemical group 0.000 description 38
- 239000000047 product Substances 0.000 description 33
- 239000013642 negative control Substances 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 16
- 238000012163 sequencing technique Methods 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 108010076504 Protein Sorting Signals Proteins 0.000 description 14
- 238000010367 cloning Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 238000001502 gel electrophoresis Methods 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000002823 phage display Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 240000002234 Allium sativum Species 0.000 description 5
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000004611 garlic Nutrition 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000037434 nonsense mutation Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002824 mRNA display Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本申请公开了一种构建抗原特异性结合多肽基因展示载体的方法，所述方法包括使用特异性识别酶切位点的限制性核酸内切酶处理得到四个具有特定粘性末端的核酸片段，使所述核酸片段定向连接。本申请还公开了根据该方法产生的抗原特异性结合多肽基因展示载体和细菌文库。本申请所述方法能够用于有效筛选抗原特异性抗原结合多肽或其片段。
Description
PCT国内申请，说明书已公开。
Claims (66)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010231148 | 2020-03-27 | ||
| CN2020102311481 | 2020-03-27 | ||
| PCT/CN2021/083246 WO2021190629A1 (zh) | 2020-03-27 | 2021-03-26 | 抗原特异性结合多肽基因展示载体的构建方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115362254A true CN115362254A (zh) | 2022-11-18 |
Family
ID=77891335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180024143.4A Pending CN115362254A (zh) | 2020-03-27 | 2021-03-26 | 抗原特异性结合多肽基因展示载体的构建方法与应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230124855A1 (zh) |
| EP (1) | EP4130260A4 (zh) |
| JP (1) | JP2023518900A (zh) |
| KR (1) | KR20220162151A (zh) |
| CN (1) | CN115362254A (zh) |
| BR (1) | BR112022019392A2 (zh) |
| MX (1) | MX2022012004A (zh) |
| WO (1) | WO2021190629A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402902A (zh) * | 2023-12-11 | 2024-01-16 | 温氏食品集团股份有限公司 | 引物组合物及其在制备t载体上的应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230310605A1 (en) | 2021-10-28 | 2023-10-05 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102282266A (zh) * | 2008-11-21 | 2011-12-14 | 德根生物科技有限公司 | 高复杂度哺乳动物展示文库及其筛选方法 |
| DK2435568T3 (da) * | 2009-05-29 | 2014-09-08 | Morphosys Ag | Samling af syntetiske antistoffer til behandling af sygdom |
| KR102115300B1 (ko) * | 2018-06-01 | 2020-05-26 | 재단법인 목암생명과학연구소 | 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법 |
-
2021
- 2021-03-26 MX MX2022012004A patent/MX2022012004A/es unknown
- 2021-03-26 KR KR1020227037512A patent/KR20220162151A/ko active Search and Examination
- 2021-03-26 BR BR112022019392A patent/BR112022019392A2/pt unknown
- 2021-03-26 JP JP2022558484A patent/JP2023518900A/ja active Pending
- 2021-03-26 US US17/914,650 patent/US20230124855A1/en active Pending
- 2021-03-26 CN CN202180024143.4A patent/CN115362254A/zh active Pending
- 2021-03-26 EP EP21776379.6A patent/EP4130260A4/en active Pending
- 2021-03-26 WO PCT/CN2021/083246 patent/WO2021190629A1/zh unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402902A (zh) * | 2023-12-11 | 2024-01-16 | 温氏食品集团股份有限公司 | 引物组合物及其在制备t载体上的应用 |
| CN117402902B (zh) * | 2023-12-11 | 2024-04-16 | 温氏食品集团股份有限公司 | 引物组合物及其在制备t载体上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021190629A1 (zh) | 2021-09-30 |
| US20230124855A1 (en) | 2023-04-20 |
| JP2023518900A (ja) | 2023-05-08 |
| MX2022012004A (es) | 2022-10-21 |
| EP4130260A4 (en) | 2024-05-15 |
| KR20220162151A (ko) | 2022-12-07 |
| EP4130260A1 (en) | 2023-02-08 |
| BR112022019392A2 (pt) | 2022-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021190629A1 (zh) | 抗原特异性结合多肽基因展示载体的构建方法与应用 | |
| KR101732552B1 (ko) | 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 | |
| EP3655532B1 (en) | A two-component vector library system for rapid assembly and diversification of full-length t-cell receptor open reading frames | |
| EP2340256A2 (en) | Improved antibody libraries | |
| CN105247050B (zh) | 用于文库构建、亲和力结合剂筛选和其表达的整合系统 | |
| WO2021092204A1 (en) | Methods and compositions for nucleic acid-guided nuclease cell targeting screen | |
| JP7411016B2 (ja) | 免疫レパートリー発掘 | |
| US20220033808A1 (en) | Methods and compositions for nucleic acid-guided nuclease cell targeting screen | |
| WO2020216191A1 (zh) | 制备噬菌体文库的方法 | |
| KR102194203B1 (ko) | 항체 나이브 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들) | |
| CN116179513B (zh) | 一种Cpf1蛋白及其在基因编辑中的应用 | |
| WO2012092323A1 (en) | Cell surface display using pdz domains | |
| CN102361980A (zh) | 不依赖信号序列的pIX噬菌体展示 | |
| CN113717256B (zh) | 一种融合蛋白及其应用 | |
| RU2775914C2 (ru) | Способ амплификации нуклеиновых кислот тяжелой и легкой цепи человеческих иммуноглобулинов для создания рекомбинантных антител, композиции праймеров (варианты) | |
| CN113930405B (zh) | 一种新型热稳定磷酸化和腺苷酰化一步法催化酶及其制备方法与应用 | |
| CN115315271A (zh) | 在哺乳动物细胞表面展示双特异性抗体的方法及载体 | |
| Rader | Generation and Selection of Phage Display Antibody Libraries in Fab Format | |
| KR20230164128A (ko) | 기능성 항원 결합 단백질 선별을 위한 벡터 및 방법 | |
| CN117979987A (zh) | 基因编辑工具 | |
| Stinson et al. | Generation of single-chain antibody fragments by PCR | |
| Smith | Molecular engineering of the catalytic antibody 20g9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40080117 Country of ref document: HK |